目的　探讨藻酸双酯钠 (PSS)治疗儿童过敏性紫癜 (HSP)高粘滞血症的疗效及预防肾损害的有效性。方法　 32例HSP患儿随机分成PSS治疗组和对照治疗组 ,另设非HSP对照组 2 0例。检测PSS治疗组和对照治疗组治疗前后的血流动力学变化 ;监测尿 β2 微球蛋白 (β2 M)、尿微量白蛋白 (Alb)。结果　PSS治疗组治疗后的血液粘度检测指标较治疗前显著下降 ,且明显低于对照治疗组 ;两组治疗前尿 β2 M和尿Alb差异无显著性 (P >0 .0 5 ) ,治疗结束直至治疗后 9个月时PSS治疗组 β2 M和尿Alb低于对照治疗组 ,两组比较差异有显著意义 (P <0 .0 1,P <0 .0 5 )。PSS治疗组 6个月直至 9个月后尿Alb与非HSP组相比无显著性差异(P >0 .0 5 )。结论　PSS对儿童HSP高粘滞血症具有较好的疗效 ,可有效预防HSP肾损害 Objective To investigate the efficacy and safety of sodium alginate (PSS) in the treatment of hyperviscosity hypercholesterolemia in children with Henoch-Schonlein purpura (HSP). Methods 32 cases of children with HSP were randomly divided into PSS treatment group and control treatment group, another non-HSP control group 20 cases. The hemodynamic changes of PSS and control groups before and after treatment were measured. Urinary β2 microglobulin (β2 M) and urinary albumin (Alb) were measured. Results The blood viscosity of the PSS treatment group decreased significantly after treatment compared with that before treatment, and was significantly lower than that of the control group. There was no significant difference in urine β2 M and urine Alb between the two groups before treatment (P> 0.05) Β2 M and urinary Alb were lower in PSS treated group than those in control group at 9 months after treatment (P <0.01, P <0.05). There was no significant difference in urinary Alb between non-HSP group and PSB-treated group after 6 months and 9 months (P> 0.05). Conclusions PSS has a good curative effect on hyperviscosity hyperlipidemia in children and can effectively prevent HSP renal damage